dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR4

Ligand: CRX-555 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Structure-activity relationship of synthetic toll-like receptor 4 agonists.
Published in: J Biol Chem

Ligand: defoslimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
Published in: Eur J Pharmacol

Ligand: GSK1795091 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.770000457763672 pEC50
Reference (Journal): The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics.
Published in: Bioorg Med Chem Lett

Ligand: LPS (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.
Published in: Science

Ligand: neoceptin-3 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS.
Published in: Proc Natl Acad Sci USA

Ligand: paclitaxel (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1992), EMA (2008)
Primary target: no
Median affinity:  -
Reference (Journal): Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol.
Published in: J Biol Chem

Ligand: resatorvid (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling.
Published in: Mol Pharmacol
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR5

Ligand: flagellin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.
Published in: Nature
Target family: Toll-like receptor family (type: catalytic_receptor)
Target: TLR7

Ligand: 852A (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.579999923706055 pEC50
Reference (Journal): Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.
Published in: Bioorg Med Chem Lett

Ligand: 852A (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.210000038146973 pEC50
Reference (Journal): Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.
Published in: Bioorg Med Chem Lett

Ligand: compound 10a [PMID: 31283223] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.090000152587891 pIC50
Reference (Journal): Novel and Selective TLR7 Antagonists among the Imidazo[1,2-<i>a</i>]pyrazines, Imidazo[1,5-<i>a</i>]quinoxalines, and Pyrazolo[1,5-<i>a</i>]quinoxalines Series.
Published in: J Med Chem

Ligand: compound 27 [WO2019226977A1] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 3.4200000762939453 pEC50
Reference (Patent): Tlr7 agonists

Ligand: GSK2245035 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma.
Published in: J Med Chem

Ligand: enpatoran (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6 pIC50
Reference (Patent): Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
Target family: TOPK family (type: enzyme)
Target: PDZ binding kinase

Ligand: OTS964 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.550000190734863 pIC50
Reference (Journal): TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis.
Published in: Sci Transl Med
Target family: Transient Receptor Potential channels (TRP) (type: vgic)
Target: TRPV4

Ligand: 4α-PDH (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pEC50
Reference (Journal): Modulation of the transient receptor potential vanilloid channel TRPV4 by 4alpha-phorbol esters: a structure-activity study.
Published in: J Med Chem
Target family: Transient Receptor Potential channels (TRP) (type: vgic)
Target: TRPC1

Ligand: 2-APB (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): TRPC1 and TRPC5 form a novel cation channel in mammalian brain.
Published in: Neuron

Ligand: Gd3+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Cloning and functional expression of a human Ca2+-permeable cation channel activated by calcium store depletion.
Published in: Neuron

Ligand: GsMTx-4 (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: La3+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): TRPC1 and TRPC5 form a novel cation channel in mammalian brain.
Published in: Neuron

Ligand: SKF96365 (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Transient Receptor Potential channels (TRP) (type: vgic)
Target: TRPC2

Ligand: 2-APB (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction.
Published in: Neuron

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: DOG (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction.
Published in: Neuron

Ligand: OAG (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction.
Published in: Neuron

Ligand: SAG (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction.
Published in: Neuron

Ligand: U73122 (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Transient Receptor Potential channels (TRP) (type: vgic)
Target: TRPM1

Ligand: pregnenolone sulphate (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Transient receptor potential melastatin 1 (TRPM1) is an ion-conducting plasma membrane channel inhibited by zinc ions.
Published in: J Biol Chem

Ligand: Zn2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6 pIC50
Target family: Transient Receptor Potential channels (TRP) (type: vgic)
Target: TRPM6

Ligand: 2-APB (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7.
Published in: J Gen Physiol

Ligand: Ca2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50

Ligand: H+ (Inorganic)
Interaction type: Activator
Action: Potentiation
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Mg2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  pIC50

Ligand: Mg2+ (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Mg2+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 3.3 pIC50
Reference (Journal): TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption.
Published in: J Biol Chem

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity:  -
Reference (Journal): TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption.
Published in: J Biol Chem

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Target family: Transient Receptor Potential channels (TRP) (type: vgic)
Target: TRPML2

Ligand: estradiol 3-methyl ether (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.230000019073486 pIC50
Reference (Journal): Estradiol analogs attenuate autophagy, cell migration and invasion by direct and selective inhibition of TRPML1, independent of estrogen receptors.
Published in: Sci Rep

Ligand: ML2-SA1 (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 1.2400000095367432 pEC50
Reference (Journal): Selective agonist of TRPML2 reveals direct role in chemokine release from innate immune cells.
Published in: Elife

Ligand: ML SA1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release.
Published in: Nat Commun

Ligand: phosphatidyl (3,5) inositol bisphosphate (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): PI(3,5)P(2) controls membrane trafficking by direct activation of mucolipin Ca(2+) release channels in the endolysosome.
Published in: Nat Commun

Ligand: PRU-10 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.269999980926514 pIC50
Reference (Journal): Estradiol analogs attenuate autophagy, cell migration and invasion by direct and selective inhibition of TRPML1, independent of estrogen receptors.
Published in: Sci Rep

Ligand: PRU-12 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.28000020980835 pIC50
Reference (Journal): Estradiol analogs attenuate autophagy, cell migration and invasion by direct and selective inhibition of TRPML1, independent of estrogen receptors.
Published in: Sci Rep
Target family: Transient Receptor Potential channels (TRP) (type: vgic)
Target: TRPP1

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity: 6 pEC50
Reference (Journal): Polycystin-2 is an intracellular calcium release channel.
Published in: Nat Cell Biol

Ligand: Cd2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Median affinity:  -
Reference (Journal): Nonspecific cation current associated with native polycystin-2 in HEK-293 cells.
Published in: J Am Soc Nephrol

Ligand: Ni2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Nonspecific cation current associated with native polycystin-2 in HEK-293 cells.
Published in: J Am Soc Nephrol

Ligand: SKF96365 (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Nonspecific cation current associated with native polycystin-2 in HEK-293 cells.
Published in: J Am Soc Nephrol
Target family: Transient Receptor Potential channels (TRP) (type: vgic)
Target: TRPP2

Ligand: amiloride (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity: 3.799999952316284 pIC50

Ligand: benzamil (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6 pIC50

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Polycystin-L is a calcium-regulated cation channel permeable to calcium ions.
Published in: Nature

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Polycystin-L is a calcium-regulated cation channel permeable to calcium ions.
Published in: Nature

Ligand: citric acid (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity: 1.7 pEC50
Reference (Journal): Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor.
Published in: Proc Natl Acad Sci USA

Ligand: ethylisopropylamiloride (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50

Ligand: flufenamate (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Median affinity:  -
Reference (Journal): Polycystin-L is a calcium-regulated cation channel permeable to calcium ions.
Published in: Nature

Ligand: Gd3+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Polycystin-L is a calcium-regulated cation channel permeable to calcium ions.
Published in: Nature

Ligand: HCl (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity: 1.89 pEC50
Reference (Journal): Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor.
Published in: Proc Natl Acad Sci USA

Ligand: La3+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Polycystin-L is a calcium-regulated cation channel permeable to calcium ions.
Published in: Nature

Ligand: malic acid (Metabolite)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor.
Published in: Proc Natl Acad Sci USA

Ligand: phenamil (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pIC50
Target family: Transient Receptor Potential channels (TRP) (type: vgic)
Target: TRPV5

Ligand: econazole (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1982)
Primary target: no
Median affinity:  -

Ligand: gentamicin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1970)
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): Gentamicin Inhibits Ca<sup>2+</sup> Channel TRPV5 and Induces Calciuresis Independent of the Calcium-Sensing Receptor-Claudin-14 Pathway.
Published in: J Am Soc Nephrol

Ligand: Mg2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: miconazole (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1974)
Primary target: no
Median affinity:  -

Ligand: oxoglaucine (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.820000171661377 pIC50
Reference (Journal): Oxoglaucine mediates Ca<sup>2+</sup> influx and activates autophagy to alleviate osteoarthritis through the TRPV5/calmodulin/CAMK-II pathway.
Published in: Br J Pharmacol

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pIC50

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: Inhibition
Ligand approved: no
Median affinity: 6.95 pIC50
Reference (Journal): Pharmacological modulation of monovalent cation currents through the epithelial Ca2+ channel ECaC1.
Published in: Br J Pharmacol

Ligand: tetrahydrocannabivarin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.400000095367432 pIC50
Reference (Journal): &#x394;<sup>9</sup>-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.
Published in: Pharmacol Res
Target family: Transient Receptor Potential channels (TRP) (type: vgic)
Target: TRPV6

Ligand: 2-APB (Synthetic organic)
Interaction type: Activator
Action: Potentiation
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: acetaldehyde (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pEC50
Reference (Journal): TRPV6 channel mediates alcohol-induced gut barrier dysfunction and systemic response.
Published in: Cell Rep

Ligand: Cd2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Primary target: no
Median affinity:  -

Ligand: ethanol (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 0.8199999928474426 pEC50
Reference (Journal): TRPV6 channel mediates alcohol-induced gut barrier dysfunction and systemic response.
Published in: Cell Rep

Ligand: GSK3527497 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pIC50
Reference (Journal): Discovery of GSK3527497: A Candidate for the Inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4).
Published in: J Med Chem

Ligand: La3+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Mg2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): Function and expression of the epithelial Ca(2+) channel family: comparison of mammalian ECaC1 and 2.
Published in: J Physiol (Lond.)

Ligand: SOR-C13 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pIC50
Reference (Journal): In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin.
Published in: PLoS ONE

Ligand: tetrahydrocannabivarin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.050000190734863 pIC50
Reference (Journal): &#x394;<sup>9</sup>-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.
Published in: Pharmacol Res

Ligand: TRPV6 inhibitor cis-22 a (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.519999980926514 pIC50
Reference (Journal): Optimization of TRPV6 Calcium Channel Inhibitors Using a 3D Ligand-Based Virtual Screening Method.
Published in: Angew Chem Int Ed Engl
Target family: Transmembrane guanylyl cyclases (type: catalytic_receptor)
Target: natriuretic peptide receptor 3

Ligand: AP811 (Peptide)
Interaction type: Antagonist
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.300000190734863 pKi
Reference (Journal): The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1.
Published in: Bioorg Med Chem Lett

Ligand: cANF4-23 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Physiological role of silent receptors of atrial natriuretic factor.
Published in: Science

Ligand: M372049 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide.
Published in: Circulation

Ligand: osteocrin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Osteocrin is a specific ligand of the natriuretic Peptide clearance receptor that modulates bone growth.
Published in: J Biol Chem

Ligand: PL-3994 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pKi
Reference (Journal): In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator.
Published in: Pulm Pharmacol Ther

Ligand: [125I]ANP (human) (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: Transmembrane guanylyl cyclases (type: catalytic_receptor)
Target: Guanylyl cyclase-B

Ligand: HS-142-1 (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor.
Published in: Biochem Biophys Res Commun